Global mRNA Therapeutics Market Size, Share, Forecast 2021 - 2033 | Top key players: Siemens, Philips, Cognizant, SAS Institute, Exscientia, Aetion Inc., Evidation Health, Komodo Health

According to a research report published by Spherical Insights & Consulting, the Global mRNA Therapeutics Market Size to Grow from USD 33.60 Billion in 2021 to USD 38.15 Billion by 2030, at a Compound Annual Growth Rate (CAGR) of 2.2% during the forecast period.

Request To Download Free Sample copy of the report: https://www.sphericalinsights.com/request-sample/1584

The mRNA Therapeutics global market research studies offer an in-depth analysis of current industry trends, development models, and methodology. Production processes, development platforms, and the actual product models are some of the variables that have a direct impact on the market. The aforementioned characteristics can drastically vary in response to even minor changes in the product profile. The study provides a thorough explanation of each of these elements of healthcare.

Market Overview
Messenger ribonucleic acid (mRNA), the basis for protein synthesis in cells, is a single protein-coding gene. Mammalian cells are used in laboratories to develop mRNA vaccines and RNA interference (RNAi) treatments, which combine the desired immunological properties. Among the often-utilized vaccination and therapy kinds are self-amplifying, non-replicating, in vivo self-replicating, and in vitro dendritic cell non-replicating mRNA. They are administered to the body in order to trigger the creation of viral antigen proteins by cells and activate immunological sensors that identify viruses. Immunity is strengthened as a result of enhanced B- and T-cell responses in the body.

The global market for mRNA therapies is expected to develop significantly during the forecast period due to an increase in infectious and chronic illness cases as well as various government initiatives for large-scale projects. Furthermore, the growing importance of COVID-19 vaccines, which Nutcracker Therapeutics and Pfizer-BioNTech launched, has led to an increase in the number of protein expression vaccine treatments being evaluated in clinical trials for cancer.

mRNA Therapeutics Market growth due to:
• Post-COVID Boom: Massive success of mRNA COVID-19 vaccines (Moderna• Nutcracker Therapeutics, Pfizer-BioNTech) accelerated global adoption and trust.
• Cancer Focus: Surge in mRNA-based cancer vaccine trials exploring personalized, tumor-specific treatments.
• Government Backing: Strong public investment in biotech and pandemic preparedness fuels R&D and infrastructure.
• Versatile Platform: mRNA's flexibility enables rapid development for emerging infectious diseases and genetic disorders.
• Faster Timelines: mRNA allows quicker response to outbreaks compared to traditional vaccines or therapies.
• Pipeline Expansion: Growing number of clinical trials targeting rare diseases, flu, HIV, and autoimmune conditions.
• Strategic Alliances: Increasing collaborations between biotech firms and pharma giants to co-develop new mRNA therapies.

Buy Now this report: https://www.sphericalinsights.com/checkout/1584

The prophylactic vaccines segment accounted the largest market share over the forecast period.

On the basis of type, the Global mRNA Therapeutics Market Size is segmented into prophylactic vccines, therapeutic vaccines, and therapeutic drugs. Among these, the prophylactic vaccines segment is dominating the market and is going to continue its dominance over the forecast period. As per the data given by Nature's opinion, the prophylactic vaccines are the result of present research and development efforts having more than 50% of mRNA businesses with minimum one preventive vaccine in development. Other vaccines for disorders including influenza and respiratory syncytial virus also contribute to the category growth, but COVID-19 products currently account for the vast bulk of preventive vaccine revenues. Rising acquisitions and mergers, as well as expanding R&D efforts by biopharmaceutical companies to enhance various preventative vaccination kinds, have all had an impact on the industry's growth. For instance, Pfizer and Valneva have declared the completion of a portfolio of investments for the development and sale of prophylactic vaccines for infectious diseases in 2022.

The infectious disease segment is dominating the market with the largest revenue share over the forecast period.

On the basis of application, the global mRNA Therapeutics Market is segmented into Infectious Diseases, Oncology. Among these, the infectious disease segment is dominating the market with the largest revenue share of 99.8% over the forecast period. The rise in the usage of mRNA vaccines, outbreak of COVID 19 pandemic, and increasing number of candidates that are entering clinical trials for different communicable diseases are going to drive the market over the forecast period. On the other hand, the oncology segment is anticipated to expand exponentially over the forecast period.

Leading players of mRNA Therapeutics Market including:
• Alnylam Pharmaceuticals
• BioNTech AG
• CureVac AG
• eTheRNA Immunotherapy
• Ethris GmbH
• In-Cell-Art
• Moderna• Nutcracker Therapeutics Therapeutics
• Sangamon therapeutic Inc.
• Sanofi AG
• SCM Lifescience Co., Ltd
• Sarepta Therapeutics
• Arcturus Therapeutics
• Ionis pharmaceuticals Inc.
• Nutcracker Therapeutics
• TIBA Biotech

Key challenges in the mRNA Therapeutics Market
• Storage & Stability Issues
mRNA molecules are highly unstable and require ultra-cold storage (e.g., -70°C for Pfizer-BioNTech), limiting distribution, especially in low-resource settings.
• Delivery System Limitations
Effective delivery of mRNA into cells remains a challenge. Lipid nanoparticles (LNPs) are widely used but still have safety and efficiency limitations.
• High Development Costs
The cost of R&D, clinical trials, and manufacturing infrastructure is significant, particularly for small biotech firms.
• Immune Reactions & Side Effects
Unintended immune responses or reactogenicity can occur, making it critical to balance efficacy with tolerability.
• Regulatory Hurdles
As a relatively new therapeutic class, regulatory frameworks are still evolving, creating uncertainty for approvals and compliance.
• Manufacturing Scalability
Scaling up from lab-scale production to mass manufacturing while maintaining quality and consistency is complex.
• Public Misinformation & Hesitancy
Despite success during COVID-19, vaccine hesitancy and misinformation about mRNA technology persist in some populations.

Research Objectives
• Market Size & Forecasting
o Estimate the global market value from 2021 to 2030, with detailed projections based on CAGR, regional growth, and segment performance.
o Assess pre- and post-COVID-19 impacts on market trajectory.
• Segmentation Analysis
o Analyze the market by type (prophylactic vs. therapeutic), application (infectious diseases, cancer, genetic disorders), end-user, and region.
o Identify the fastest-growing segments and their contribution to overall growth.
• Trend & Innovation Mapping
o Evaluate the emerging trends in mRNA technology, including self-amplifying mRNA, novel delivery systems (e.g., lipid nanoparticles), and personalized cancer vaccines.
o Track R&D investment patterns, regulatory support, and biotech partnerships.
• Competitive Landscape Assessment
o Profile major players such as Nutcracker Therapeutics, Pfizer/BioNTech, CureVac, Sanofi, and Arcturus, including pipeline analysis, strategic initiatives, and global footprint.
o Understand competitive advantages and innovation pipelines.

Recent Development
• In November 2022, Nutcracker Therapeutics Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine is approved for use by Health Canada as a booster dose in people 18 years of age and older. Similar bivalent booster doses from Nutcracker Therapeutics (50 mcg) and Pfizer-BioNTech (30 mcg) with Omicron BA.1 or BA.4/5 variants were already approved by Health Canada in September and October of 2022, respectively.

Access Full Report: https://www.sphericalinsights.com/reports/mrna-therapeutics-market

Market Segment
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global mRNA Therapeutics market based on the below-mentioned segments:

mRNA Therapeutics Market, Application Analysis
• Infectious Diseases
• Oncology

mRNA Therapeutics Market, Type Analysis
• Prophylactic vaccines
• Therapeutic vaccines
• Therapeutic drugs

mRNA Therapeutics Market, End User Analysis
• Hospitals and clinics
• Research organizations
• Others

Regional Segment Analysis of the mRNA Therapeutics Market
• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

What's covered in the report?
1. Overview of the MRNA Therapeutics Market.
2. The current and forecasted regional (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa) market size data for the MRNA Therapeutics Market, based on segment.
3. MRNA Therapeutics Market trends.
4. MRNA Therapeutics Market drivers.
5. Analysis of major company profiles.

FIVE FORCES ANALYSIS
1. Competitive Rivalry - High
o Many strong players (Moderna• Nutcracker Therapeutics• Nutcracker Therapeutics, Pfizer, CureVac).
o Rapid innovation and expanding pipelines.
o High R&D spending and patent activity.
2. Threat of New Entrants - Moderate
o High costs, complex regulations, and IP barriers.
o Startups entering via partnerships and niche areas.
3. Bargaining Power of Suppliers - Moderate to High
o Limited suppliers for key materials (lipids, enzymes).
o High dependence on specialized inputs.
4. Bargaining Power of Buyers - Moderate
o Buyers gaining more power post-COVID.
o Governments, hospitals, and pharma firms drive demand.
5. Threat of Substitutes - Low to Moderate
o Alternatives like DNA vaccines exist.
o But mRNA offers faster development and higher adaptability.

PESTLE ANALYSIS
1. Political
• Favorable policies for fast-track approvals (e.g., Emergency Use Authorization).
• Geopolitical tensions may affect global supply chains and vaccine equity.
2. Economic
• High R&D and manufacturing costs raise entry barriers.
• Strong market growth projections post-COVID across therapeutic areas.
• Economic downturns may reduce public health spending in low-income regions.
3. Social
• Increased public awareness of vaccines and preventive care.
• Rising prevalence of chronic and infectious diseases drives demand.
• Vaccine hesitancy and misinformation remain concerns in some regions.
4. Technological
• Rapid advances in lipid nanoparticle delivery and self-amplifying mRNA.
• Enhanced AI and bioinformatics integration in vaccine design.
• Cold-chain logistics and storage tech still face limitations.
5. Legal
• Strict FDA, EMA, and global regulatory frameworks govern development.
• Patent protections play a key role major players hold core IP rights.
• Legal scrutiny over data transparency and trial ethics is increasing.
6. Environmental
• Cold storage and logistics contribute to carbon emissions.
• Shift toward eco-friendly packaging and transport solutions.
• Increased focus on sustainable pharmaceutical manufacturing.

Table of Content (TOC)
• Introduction
1. Objectives of the Study
2. Market Definition
3. Research Scope
• Research Methodology and Assumptions
• Executive Summary
• Premium Insights
1. Porter's Five Forces Analysis
2. Value Chain Analysis
3. Top Investment Pockets
1. Market Attractiveness Analysis By Product Type
2. Market Attractiveness Analysis By Type
3. Market Attractiveness Analysis By Segment Type
4. Market Attractiveness Analysis By Region
4. Industry Trends
• Market Dynamics
1. Market Evaluation
2. Drivers
1. Increasing development in sector
3. Restraints
4. Opportunities
5. Challenges
• Global MRNA Therapeutics Market Analysis and Projection, By Product Type
• Global MRNA Therapeutics Market Analysis and Projection, By Type
• Global MRNA Therapeutics Market Analysis and Projection, By Segment Type
• Global MRNA Therapeutics Market Analysis and Projection, By Regional Analysis
1. Segment Overview
2. North America
1. U.S.
2. Canada
3. Mexico
3. Europe
1. Germany
2. France
3. U.K.
4. Italy
5. Spain
4. Asia-Pacific
1. Japan
2. China
3. India
5. South America
1. Brazil
6. Middle East and Africa
1. UAE
2. South Africa
• Global MRNA Therapeutics Market-Competitive Landscape
1. Overview
2. Market Share of Key Players in the Global MRNA Therapeutics Market
1. Global Company Market Share
2. North America Company Market Share
3. Europe Company Market Share
4. APAC Company Market Share
3. Competitive Situations and Trends
1. Coverage Launches and Developments
2. Partnerships, Collaborations, and Agreements
3. Mergers & Acquisitions
4. Expansions
• Company Profiles
1. Company1
1. Business Overview
2. Company Snapshot
3. Company Market Share Analysis
4. Company Coverage Portfolio
5. Recent Developments
6. SWOT Analysis
2. Company2
1. Business Overview
2. Company Snapshot
3. Company Market Share Analysis
4. Company Coverage Portfolio
5. Recent Developments
6. SWOT Analysis
3. Company3
1. Business Overview
2. Company Snapshot
3. Company Market Share Analysis
4. Company Coverage Portfolio
5. Recent Developments
6. SWOT Analysis

Industry Related Reports

Global Oral Doxycycline Hyclate Market Size
https://www.sphericalinsights.com/reports/oral-doxycycline-hyclate-market

Global Digital Denture Market Size
https://www.sphericalinsights.com/reports/digital-denture-market

Global Patient Data Hub Solutions Market Size
https://www.sphericalinsights.com/reports/patient-data-hub-solutions-market

About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.

CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Follow Us: LinkedIn | Facebook | Twitter

This release was published on openPR.